University of Michigan

Publications

University of Birmingham / NIHR Birmingham BRC University of Michigan Madrigal

NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US

Emory University of Oklahoma HSC University of Michigan University of Pittsburgh/Nicklaus Children’s Hospital Cleveland Clinic

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease

Heinrich Heine University Düsseldorf University of Michigan Vanderbilt University Medical Center GSK UNC University of Birmingham VCU Mercy Medical Center / University of Maryland

Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis

Heinrich Heine University Düsseldorf University of Michigan University of North Carolina University of Florida University of California San Diego University of Minnesota

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

University of Michigan University of North Carolina Emory University University of Florida Saint Louis University University of Pennsylvania Washington University in St. Louis University of California San Diego Virginia Commonwealth University Atlanta Gastroenterology Associates

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study

Total Publications

Abstract/Manuscript

Poster Presentation

2023 · Poster Presentation · University of Birmingham / NIHR Birmingham BRC · Hepatology

NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US

2022 · Abstract/Manuscript · Emory

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease

2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf

Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis

2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

2021 · Abstract/Manuscript · University of Michigan

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study

2021 · Abstract/Manuscript · University of Michigan

Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort

2021 · Abstract/Manuscript · Zucker School of Medicine at Hofstra

Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV

2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology

Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice

2020 · Abstract/Manuscript · University of Michigan

Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease

2020 · Abstract/Manuscript · University of Michigan

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases

2020 · Abstract/Manuscript · University of Michigan

A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

2019 · Poster Presentation · University of Michigan · Hepatology

Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort

2019 · Poster Presentation · Emory · Hepatology

Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH

2019 · Poster Presentation · University of Michigan · Hepatology

The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease

2019 · Poster Presentation · University of Michigan · Hepatology

Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity

2019 · Poster Presentation · University of Michigan · Hepatology

Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD

2019 · Poster Presentation · Zucker School of Medicine at Hofstra · Hepatology

Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study (AASLD)

2018 · Poster Presentation · Columbia University Medical Center · Hepatology

Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM)

2018 · Poster Presentation · University of Michigan · Hepatology

Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH

2018 · Poster Presentation · University of Michigan · Hepatology

Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)

2017 · Poster Presentation · University of Michigan · Hepatology

Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH

2017 · Poster Presentation · University of Michigan · Hepatology

Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (HEP DART)

2017 · Abstract/Manuscript · Emory

University of Michigan — Publications

Publications

NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease

Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study

NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease

Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis

Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study

Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort

Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV

Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice

Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases

A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort

Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH

The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease

Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity

Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD

Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study (AASLD)

Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM)

Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH

Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)

Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH

Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (HEP DART)

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study